Skip to content

Opus Genetics IRD Debt-to-assets

Debt-to-assets at other companies

AbbVie logo
AbbVieABBV
0.5×0.0×
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
0.3×-0.1×
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
0.0×
Opko Health logo
Opko HealthOPK
0.0×
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
0.2×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Calculated from Opus Genetics’s reported figures.

Based on the most recent quarter.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's debt-to-assets?
Opus Genetics (IRD) reported debt-to-assets of 0× in Q1 2026.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.